The VPREB1 deletion in REH, which also encompasses part of the pseudogene PRAMENP, is adjacent to another 192-kb deletion, affecting the chronic lymphocytic leukemia-associated gene IGLL5 (Kasar et al, 2015); the gene that lies between these two deletions, PRAME, has been identified as a potential therapeutic target for pediatric ALL (Steinbach et al, 2002). The gene discussed is VPREB1; the disease is B-cell chronic lymphocytic leukemia.